298 related articles for article (PubMed ID: 34179738)
1. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
[TBL] [Abstract][Full Text] [Related]
3. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
[TBL] [Abstract][Full Text] [Related]
4. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
6. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
7. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence of Advanced Liver Fibrosis Among Patients With Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia.
Lee XH; Nor LM; Ang CS; Yeow TP; Lim SL
J ASEAN Fed Endocr Soc; 2023; 38(1):52-61. PubMed ID: 37252406
[TBL] [Abstract][Full Text] [Related]
10. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
[TBL] [Abstract][Full Text] [Related]
11. Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease.
Alam MS; Kamrul-Hasan ABM; Kalam ST; Rahman SMM; Hoque MI; Islam MB; Paul AK
Diabetes Metab Syndr Obes; 2021; 14():3089-3096. PubMed ID: 34262313
[TBL] [Abstract][Full Text] [Related]
12. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease.
Seki K; Shima T; Oya H; Mitsumoto Y; Mizuno M; Okanoue T
Hepatol Res; 2017 Aug; 47(9):882-889. PubMed ID: 27753194
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
15. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
Vieira Barbosa J; Lai M
Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
[TBL] [Abstract][Full Text] [Related]
17. Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
Chhabra S; Singh SP; Singh A; Mehta V; Kaur A; Bansal N; Sood A
J Clin Exp Hepatol; 2022; 12(2):409-416. PubMed ID: 35535092
[TBL] [Abstract][Full Text] [Related]
18. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
[TBL] [Abstract][Full Text] [Related]
19. Case-finding strategies in non-alcoholic fatty liver disease.
Boursier J; Tsochatzis EA
JHEP Rep; 2021 Apr; 3(2):100219. PubMed ID: 33659890
[TBL] [Abstract][Full Text] [Related]
20. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
